{
      "Rank": 328,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals",
            "human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals",
            "normal saline 2mL, doses separated by 4 weeks for a total of 3 doses"
      ],
      "ArmGroupInterventionName": [
            "Biological: human umbilical cord blood derived mesenchymal stem cells",
            "Biological: human umbilical cord blood derived mesenchymal stem cells",
            "Other: Normal saline 2mL"
      ],
      "ArmGroupLabel": [
            "NEUROSTEM\u00ae (hUCB-MSCs)- low dose",
            "NEUROSTEM\u00ae (hUCB-MSCs) - high dose",
            "Placebo"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03172117"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "A long-term follow-up study to obtain safety and efficacy data in subjects who completed phase 1/2a clinical trial of NEUROSTEM\u00ae (NCT02054208), comparing NEUROSTEM and placebo groups for up to 36 months after the initial administration in patients suffering from Alzheimer's disease"
      ],
      "BriefTitle": [
            "Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM\u00ae Phase-I/IIa Clinical Trial."
      ],
      "CentralContactEMail": [
            "sjchoi@medi-post.co.kr"
      ],
      "CentralContactName": [
            "Sujin Choi, MD"
      ],
      "CentralContactPhone": [
            "+82-2-3465-6770"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact"
      ],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "December 31, 2021"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Alzheimer's Disease"
      ],
      "ConditionAncestorId": [
            "D000003704",
            "D000001927",
            "D000002493",
            "D000009422",
            "D000024801",
            "D000019636",
            "D000019965",
            "D000001523"
      ],
      "ConditionAncestorTerm": [
            "Dementia",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Nervous System Diseases",
            "Tauopathies",
            "Neurodegenerative Diseases",
            "Neurocognitive Disorders",
            "Mental Disorders"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC10",
            "BXM",
            "All",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Nervous System Diseases",
            "Behaviors and Mental Disorders",
            "All Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Alzheimer's Disease"
      ],
      "ConditionBrowseLeafId": [
            "M3037",
            "M6056",
            "M4356",
            "M4894",
            "M22155",
            "M20711",
            "M20989",
            "M13625",
            "M3967",
            "T2192"
      ],
      "ConditionBrowseLeafName": [
            "Alzheimer Disease",
            "Dementia",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Tauopathies",
            "Neurodegenerative Diseases",
            "Neurocognitive Disorders",
            "Psychotic Disorders",
            "Mental Disorders",
            "Familial Alzheimer Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000000544"
      ],
      "ConditionMeshTerm": [
            "Alzheimer Disease"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "The subjects will be followed up at 12-month, 24-month, and 36-month (phone call) after the initial administration of NEUROSTEM\u00ae."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nAssessment of safety and exploratory treatment efficacy in subjects who were enrolled and completed phase 1/2a clinical trial of NEUROSTEM\u00ae.\nSubjects who have been treated with either NEUROSTEM\u00ae or placebo at least 12 months ago.\nSubjects who voluntarily decided to participate and signed the consent form after receiving explanations on the clinical trial (in case it is difficult for the participant to sign, the consent of the legal representative)\n\nExclusion Criteria:\n\nSubjects who were not enrolled in phase 1/2a clinical trial of Neurostem\u00ae for assessing safety and exploratory treatment efficacy\nOther subjects, excluding those listed above, who were deemed unsuitable by the PI"
      ],
      "EnrollmentCount": [
            "45"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "NEUROSTEM\u00ae (hUCB-MSCs) - high dose",
            "NEUROSTEM\u00ae (hUCB-MSCs)- low dose",
            "Placebo"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals\n\nHigh dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals",
            "Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "human umbilical cord blood derived mesenchymal stem cells",
            "Normal saline 2mL"
      ],
      "InterventionOtherName": [
            "NEUROSTEM\u00ae"
      ],
      "InterventionType": [
            "Biological",
            "Other"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [
            "Recruiting"
      ],
      "LastUpdatePostDate": [
            "August 28, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "August 26, 2020"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Medipost Co Ltd."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Seoul"
      ],
      "LocationContactEMail": [
            "evekhj@gmail.com"
      ],
      "LocationContactName": [
            "Heejin Choi, MD",
            "Duk L Na, MD"
      ],
      "LocationContactPhone": [
            "+82-2-3410-1947"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Principal Investigator"
      ],
      "LocationCountry": [
            "Korea, Republic of"
      ],
      "LocationFacility": [
            "Samsung Medical Center"
      ],
      "LocationState": [],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [],
      "MaximumAge": [
            "86 Years"
      ],
      "MinimumAge": [
            "50 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM\u00ae Phase-I/IIa Clinical Trial."
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Medipost Co Ltd."
      ],
      "OrgStudyId": [
            "MP-CR-010-F/U"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [],
      "OverallOfficialName": [],
      "OverallOfficialRole": [],
      "OverallStatus": [
            "Unknown status"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 31, 2021"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Alzheimer's Disease assessment Scale-Cognitive Subscale"
      ],
      "PrimaryOutcomeMeasure": [
            "Change from the baseline in ADAS-Cog"
      ],
      "PrimaryOutcomeTimeFrame": [
            "24 month after the first dose"
      ],
      "ReferenceCitation": [
            "Kim HJ, Cho KR, Jang H, Lee NK, Jung YH, Kim JP, Lee JI, Chang JW, Park S, Kim ST, Moon SW, Seo SW, Choi SJ, Na DL. Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial. Alzheimers Res Ther. 2021 Sep 14;13(1):154. doi: 10.1186/s13195-021-00897-2."
      ],
      "ReferencePMID": [
            "34521461"
      ],
      "ReferenceType": [
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Seoul Instrumental Activities of Daily Living",
            "Mini Mental State Exmination Korean version",
            "Caregiver-administered Neuropsychiatric Inventory",
            "the ADAS-cog score at 24 month after the first administration compared to the baseline",
            "Clinical Dementia Rating-Sum of Box",
            "The Clinician's Interview Based Impression of Change-plus",
            "Florbetaben - Pittsburgh Compound B-positron emission tomography",
            "fluorodeoxyglucose positron emission tomography",
            "MRI Analysis",
            "biomakrer analysis"
      ],
      "SecondaryOutcomeMeasure": [
            "Change from the baseline in S-IADL",
            "Change from the baseline in K-MMSE",
            "Change from the baseline in CGA-NPI",
            "ADAS-Cog Response Rate",
            "Change in CDR-SOB",
            "Change in CIBIC-plus",
            "Change in Florbetaben-PET",
            "Change in FDG-PET (CMRglc: regional cerebral metabolic rate for glucose)",
            "Change from baseline in MRI (DTI mapping)",
            "Change from the baseline in CSF biomarkers"
      ],
      "SecondaryOutcomeTimeFrame": [
            "24 month after the first dose",
            "24 month after the first dose",
            "24 month after the first dose",
            "24 month after the first dose",
            "24 month after the first dose",
            "24 month after the first dose",
            "24 month after the first dose",
            "24 month after the first dose",
            "24 month after the first dose",
            "24 month after the first dose"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "May 19, 2017"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "August 2020"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "June 1, 2017"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "May 29, 2017"
      ],
      "StudyFirstSubmitQCDate": [
            "May 29, 2017"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": []
}